Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Exenatide For Reducing the Reinforcing Effects of Cocaine
NCT06252623 · Christopher D. Verrico · PHASE1 · withdrawn · last registry update 2026-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was closed due to the inability to acquire the study drug.” | – | Registry record, Christopher D. Verrico |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GLP1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Results posted on the registry: Eli Lilly and Company, Retatrutide + Placebo (NCT05936151)
- 2026-11-06Results posted on the registry: University of Minnesota, Semaglutide and Behavioral Program (NCT04873245)
- 2026-11-05Phase 3 first posted: Novo Nordisk A/S, CagriSema + Semaglutide (NCT07919405)
- 2026-11-02Results posted on the registry: Novo Nordisk A/S, Semaglutide + Placebo (Semaglutide) (NCT04916470)
- 2026-10-28Results posted on the registry: Adrian Vella, Exendin-9,39 + Liraglutide (NCT04466566)
- 2026-10-26Results posted on the registry: University College, London, Semaglutide 3 mg + Placebo (NCT05073835)
- 2026-10-23Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Semaglutide + Placebo (NCT07891156)
- 2026-10-22Phase 3 first posted: Hoffmann-La Roche, Enicepatide + Tirzepatide (NCT07889648)
- 2026-10-19Phase 3 first posted: Eli Lilly and Company, eloralintide and tirzepatide + Tirzepatide (NCT07881458)
- 2026-10-19Phase 3 first posted: Eli Lilly and Company, eloralintide and tirzepatide + Eloralintide (NCT07881432)
- 2026-10-08Phase 3 first posted: Amgen, Maridebart cafraglutide + Semaglutide (NCT07866066)
- 2026-10-02Phase 3 first posted: Boehringer Ingelheim, Survodutide (NCT07855900)
- 2026-09-30Phase 3 first posted: Boehringer Ingelheim, Survodutide + Placebo matching survodutide (NCT07850063)
- 2026-09-30Phase 3 first posted: Boehringer Ingelheim, Survodutide + Placebo (NCT07850050)
- 2026-09-29Phase 3 first posted: Pfizer, Semaglutide + Berobenatide (NCT07845500)
- 2026-09-29Phase 3 first posted: Woolcock Institute of Medical Research, Tirzepatide (NCT07846865)
- 2026-09-29Phase 3 first posted: University Hospital, Angers, Semaglutide (Wegovy) weekly injection + Placebo weekly Injection (NCT07845994)
- 2026-09-29Results posted on the registry: Zomagen Biosciences Ltd., Placebo + VTX3232 30 mg (NCT06771115)
- 2026-09-22Phase 3 first posted: Zagazig University, Dulaglutide + Semagludtide (NCT07834398)
- 2026-09-18Phase 3 first posted: Universidade do Porto, Tirzepatide + Placebo (NCT07829198)
- 2026-09-15Results posted on the registry: Eli Lilly and Company, Orforglipron + Semaglutide (NCT06045221)
- 2026-09-15Phase 3 first posted: Zagazig University, Dulaglutide 1.5 MG/ML + Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution (NCT07820111)
- 2026-09-14Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Placebo (NCT07817875)
- 2026-09-14Phase 3 first posted: Novo Nordisk A/S, CagriSema (NCT07817251)
- 2026-09-01Phase 3 first posted: University of Massachusetts, Worcester, Semaglutide (Wegovy) weekly injection (NCT07797036)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision